Novartis expands Scemblix label to first-line CML patients
Novartis’ chronic myeloid leukemia drug Scemblix will now be available to newly diagnosed patients, the FDA announced on Tuesday.
Scemblix was first approved in 2021 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
